---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Pharmacology questions"
description: "Pharmacology questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Ubrelvy work (mechanism of action)? Is Ubrelvy known to constrict blood vessels? How is Ubrelvy metabolized and eliminated? How long does Ubrelvy stay in your system (half-life)? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Pharmacology questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Mechanism

<a id="ubrelvy-mechanism"></a>

### How does Ubrelvy work (mechanism of action)?

> “Ubrogepant is a calcitonin gene-related peptide receptor antagonist.”

Source: [UBRELVY: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=8)

> “DURING A MIGRAINE ATTACK, CGRP IS RELEASED FROM ONE NEURON AND TRAVELS TO THE NEXT, SENDING OUT A PAIN SIGNAL<sup>1</sup>”

Source: [UBRELVY: UBRELVY® Mechanism of Action, captured 2026-11-14](https://www.ubrelvyhcp.com/moa#:~:text=DURING%20A%20MIGRAINE%20ATTACK%2C%20CGRP,NEXT%2C%20SENDING%20OUT%20A%20PAIN)

> “UBRELVY directly blocks CGRP by binding to its receptor on the postsynaptic neuron, thereby blocking pain signaling.<sup>2,3</sup>
>
> The clinical significance is not known.”

Source: [UBRELVY: UBRELVY® Mechanism of Action, captured 2026-11-14](https://www.ubrelvyhcp.com/moa#:~:text=UBRELVY%20directly%20blocks%20CGRP%20by,clinical%20significance%20is%20not%20known.)

Note: The first passage is from the Prescribing Information; the others are from the mechanism of action page of the Ubrelvy HCP site.

<a id="ubrelvy-blood-vessels"></a>

### Is Ubrelvy known to constrict blood vessels?

> “UBRELVY IS NOT KNOWN TO CONSTRICT BLOOD VESSELS
>
> WHEN ACTING ON THE MIGRAINE DISEASE PATHWAY.<sup>4</sup>
>
> The clinical significance of this mechanism of action is unknown.
> See Important Safety Information for Warnings and Precautions.”

Source: [UBRELVY: UBRELVY® Mechanism of Action, captured 2026-11-14](https://www.ubrelvyhcp.com/moa#:~:text=UBRELVY%20IS%20NOT%20KNOWN%20TO,Information%20for%20Warnings%20and%20Precautions.)

Note: The statement is on the mechanism of action page of the Ubrelvy HCP site, under a heading comparing UBRELVY with triptans, and cites the American Headache Society position statement on integrating new migraine treatments into clinical practice (Headache 2019). The Prescribing Information makes no statement about vasoconstriction; it lists hypertension and Raynaud's phenomenon, reported after use of CGRP antagonists including UBRELVY, under Warnings and Precautions.

## Pharmacokinetics

<a id="ubrelvy-metabolism"></a>

### How is Ubrelvy metabolized and eliminated?

> “Ubrogepant is eliminated mainly through metabolism, primarily by CYP3A4. The parent 
> compound (ubrogepant), and 2 glucuronide conjugate metabolites were the most prevalent 
> circulating components in human plasma. The glucuronide metabolites are not expected to 
> contribute to the pharmacological activity of ubrogepant since they were reported as about 6000-
> fold less potent in the CGRP receptor binding assay.”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

> “The elimination half-life of ubrogepant is approximately 5-7 hours. The mean apparent oral 
> clearance (CL/F) of ubrogepant is approximately 87 L/hr. Ubrogepant is excreted mostly via the 
> biliary/fecal route, while the renal route is a minor route of elimination. Following single oral 
> dose administration of [<sup>14</sup>C]-ubrogepant to healthy male subjects, 42% and 6% of the dose was 
> recovered as unchanged ubrogepant in feces and urine, respectively.”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

<a id="ubrelvy-half-life"></a>

### How long does Ubrelvy stay in your system (half-life)?

> “The elimination half-life of ubrogepant is approximately 5-7 hours.”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

> “5 to 7 HOURS:
> elimination half-life<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=5%20to%207%20HOURS%3A,elimination)

<a id="ubrelvy-absorption"></a>

### How fast is Ubrelvy absorbed (time to peak concentration)?

> “Following oral administration of UBRELVY, ubrogepant is absorbed with peak plasma 
> concentrations at approximately 1.5 hours. Ubrogepant displays dose-proportional 
> pharmacokinetics within the recommended dose range [see Dosage and Administration (2.1)].”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

> “1.5 HOURS:
> time to peak plasma concentrations<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=1.5%20HOURS%3A,time%20to%20peak%20plasma)

## Components

<a id="ubrelvy-inactive-ingredients"></a>

### What are the inactive ingredients in Ubrelvy?

> “UBRELVY is available as tablets for oral administration containing 50 mg or 100 mg 
> ubrogepant. The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, 
> mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium 
> chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.”

Source: [UBRELVY: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=8)

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
